SCHEMBL10003229

SCHEMBL10003229

CCOC(=O)c1c(OCC(F)(F)F)c2cc(NC(=O)c3ccco3)c(CC)nc2n1C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 4/20 0.46
▸ NPC1 O15118 3/20 0.46
▸ ALDH1A1 P00352 9/20 0.42
▸ KDM4E B2RXH2 8/20 0.42
▸ HSD17B10 Q99714 4/20 0.42
▸ MAPT P10636 3/20 0.42
▸ SMN1; SMN2 Q16637 3/20 0.42
▸ USP2 O75604 1/20 0.42
▸ TP53 P04637 1/20 0.42
▸ KMT2A Q03164 5/20 0.42
▸ LMNA P02545 4/20 0.42
▸ TSHR P16473 4/20 0.42
▸ MEN1 O00255 4/20 0.42
▸ HPGD P15428 6/20 0.41
▸ APAF1 O14727 2/20 0.41
▸ GLA P06280 2/20 0.41
▸ NSD2 O96028 1/20 0.41
▸ THRB P10828 1/20 0.41
▸ CASP1 P29466 1/20 0.41
▸ AGTR1 P30556 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10003502 0.91 TSHR (0.40) RAB9ANPC1ALDH1A1KDM4EHSD17B10
SCHEMBL10003336 0.88 SMN1; SMN2 (0.41) RAB9ANPC1ALDH1A1KDM4EHSD17B10
SCHEMBL10004404 0.86 PTK2 (0.42) RAB9ANPC1ALDH1A1KDM4EMAPT
SCHEMBL10003125 0.85 RAB9A (0.42) RAB9ANPC1ALDH1A1KDM4EMAPT
SCHEMBL10003062 0.85 LMNA (0.46) RAB9ANPC1ALDH1A1KDM4EMAPT
SCHEMBL10003859 0.85 SMN1; SMN2 (0.51) RAB9ANPC1ALDH1A1KDM4EMAPT
SCHEMBL10004017 0.85 SMN1; SMN2 (0.44) RAB9ANPC1ALDH1A1KDM4EHSD17B10
SCHEMBL10002933 0.84 ALDH1A1 (0.40) RAB9ANPC1ALDH1A1KDM4EMAPT
SCHEMBL10002880 0.84 TSHR (0.47) RAB9ANPC1ALDH1A1KDM4EHSD17B10
SCHEMBL10003510 0.84 SMN1; SMN2 (0.37) RAB9ANPC1ALDH1A1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2471789-B9 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2015-03-25 — — EP disclosed
EP-2471789-B1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2014-09-17 — — EP disclosed
US-8486965-B2 Pyrrolo[2,3-b]pyridine derivative and use thereof for treatment of cancer TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-07-16 — — US disclosed
US-20120220569-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-08-30 — — US disclosed
EP-2471789-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2012-07-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220569-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF SMO, GLI1, SHH RAB9A 1389/4885NPC1 1300/4885ALDH1A1 321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback